Patents Assigned to Inis Biotech LLC
  • Patent number: 11020478
    Abstract: A method for modulating angiogenesis in a cancer or tumor refractory to anti-VEGF, including identifying a cancer cell as being referactory to anti-VEGF, and then contacting the cancer cell refractory to anti-VEGF with an effective amount of an agent that modulates interaction between Gal1 or a Gal1 fragment and the natural binding partner of Gal1 or the Gal1 fragment to thereby modulate angiogenesis.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: June 1, 2021
    Assignees: Inis Biotech LLC, Consejo Nacional de Investigaciones Científicas y Técnicas, Funadción Sales
    Inventors: Gabriel Adrian Rabinovich, Diego Omar Croci Russo, Juan Pablo Cerliani, Mariana Salatino, Pablo Francisco Hockl, Juan Manuel Pérez Sáez
  • Patent number: 10857522
    Abstract: A process for producing propylene glycol from glycerol including a catalyst of Cu and Ce at concentrations of up to 15% of each metal. In addition, it is described a catalyst of Cu and Ce to perform the selective reduction of glycerol and the process of production of such catalyst.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: December 8, 2020
    Assignees: CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET), UNIVERSIDAD NACIONAL DEL LITORAL, INIS BIOTECH LLC.
    Inventors: Raul Alberto Comelli, Lisandro Roberto Ferrari
  • Patent number: 10490866
    Abstract: A method for the acid dissolution of LiCoO2 contained in the cathode of lithium ion batteries, using acetic or tartaric acid as leaching agent, the method being characterized in that it comprises a first stage and a second stage, wherein said first stage comprises the step of separating the cathode components, while said second stage comprises the step of dissolving the pure LiCoO2 with at least one acid. The method allows achieving an economically viable complete recycling process with low environmental impact.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: November 26, 2019
    Assignees: CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS (CONICET), UNIVERSIDAD NACIONAL DE CUYO, INIS BIOTECH LLC
    Inventors: Mario Humberto Rodriguez, Daniela S. Suarez, Eliana G. Pinna, Celina N. Zeballos
  • Patent number: 10385114
    Abstract: The invention relates to the identification of Secreted Protein, Acidic and Rich in Cysteine (SPARC) as a new therapeutic target in patients with fulminant hepatitis and allows the development of a strategy destined to protect the liver form damage. The invention relates to the treatment of acute liver failure or fulminant hepatitis by administering to a subject in need thereof an agent that inhibits at least partially the expression of SPARC and/or interferes with its biological function.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: August 20, 2019
    Assignees: INIS BIOTECH LLC, CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET), FUNDACION INSTITUTO LELOIR (FIL), ASOCIACION CIVIL DE ESTUDIOS SUPERIORES (ACES)
    Inventors: Guillermo Daniel Mazzolini, Estanislao Peixoto, Jorge Aquino, Maria C. Atorrasagasti, Osvaldo Podhjacer
  • Patent number: 10294295
    Abstract: A method for modulating angiogenesis in a cancer or tumor refractory to anti-VEGF, including identifying a cancer cell as being referactory to anti-VEGF, and then contacting the cancer cell refractory to anti-VEGF with an effective amount of an agent that modulates interaction between Gal1 or a Gal1 fragment and the natural binding partner of Gal1 or the Gal1 fragment to thereby modulate angiogenesis.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: May 21, 2019
    Assignees: INIS Biotech LLC, Consejo Nacional de Investigaciones Cientificas Y Tecnicas, Fundacion Sales
    Inventors: Gabriel Adrian Rabinovich, Diego Omar Croci Russo, Juan Pablo Cerliani, Mariana Salatino
  • Patent number: 10259719
    Abstract: Process for obtaining lithium compounds and intermediate compounds, comprising the following steps: a) contacting aluminosilicate particles, for example ?-spodumene, with at least one fluorine compound, for example HF, NaF or others; b) stirring the mixture increasing the temperature until reaching an appropriate temperature; c) carrying out at least a precipitation and filtration process of the mixture of step b), and, d) recovering the lithium compound. The process may comprise using HF at a concentration between 5 and 30% v/v or NaF at a concentration between 5 and 30% w/v; a solid/liquid ratio of step a) between 0.9 and 14.4% w/v; a particle size of between 29 and 200 ?m. The final lithium product of the process may be lithium carbonate or lithium fluoride.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: April 16, 2019
    Assignees: Inis Biotech LLC, Consejo Nacional De Investigaciones Cientificas Y Technicas (Conicet), Universidad Nacional De Cuyo
    Inventors: Mario Humberto Rodriguez, Gustavo Daniel Rosales, Maria del Carmen Ruiz
  • Patent number: 10233227
    Abstract: An isoform of the TGF beta receptor II comprising a sequence of about of 80 amino acids and lacking a transmembrane domain; wherein the isoform is a TGF?-1 agonist. The isoform comprises the amino acid sequence set forth in SEQ ID No. 12. The isoform may have the amino acid sequence set forth in SEQ ID No. 2 or sequences having at least 85% sequence identity to the sequence set forth in SEQ ID No. 2.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: March 19, 2019
    Assignees: CONSEJO Nacional de Investigaciones Cientificas y Tecnicas, FUNDACION ARTICULAR, INIS BIOTECH LLC
    Inventors: Ricardo Alfredo Dewey, Benito Jorge Velasco Zamora, Tania Melina Rodríguez, Alejandra Carrea, Andrea Nancy Chisari, Marcelo Javier Perone
  • Patent number: 10000548
    Abstract: Galectin-1 polypeptide variants that include a mutation of the histidine residue corresponding to position 52 of the full-length amino acid sequence of native human Gal-1 as shown in SEQ ID NO: 1, the mutation being a substitution of the histidine to tyrosine or asparagine, providing resistance to acidosis otherwise resulting in deactivation of the native human Gal-1. The Galectin-1 polypeptide variants may include one or more additional mutation(s) of the cysteine residue corresponding to a position selected from 2, 16, 88, or combinations thereof of the full-length amino acid sequence of native human Gal-1 as shown in SEQ ID NO: 1, the additional mutation being a substitution of the cysteine to serine, and providing resistance to oxidation.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: June 19, 2018
    Assignees: Consejo Nacional de Investigaciones Cientificas Y Técnicas, Fundación Sales, INIS Biotech LLC
    Inventors: Gabriel Adrián Rabinovich, Santiago Di Lella, Dario Ariel Estrin, Julio Javier Carmelo, Santiago Patricio Mendez Huergo
  • Publication number: 20180147556
    Abstract: Bi-structured matrix for purification and handling of solid reagents, which comprises at least a polymer solid carrier coated with at least one hydrosoluble polymer, and manufacturing processes. The solid carrier may be, among others, cross-linked polyurethane foam or a micropipette tip. The hydrosoluble polymer may be, among others, polyvinylalcohol, agarose, hydroxyethylcellulose or combinations thereof. The matrix may further comprise a polymer produced from monomers of glycidyl metacrylate (GMA), dimethyl acrylamide (DMAAm), 2-hydroxyethyl metacrylate, metacrylic acid, or combinations thereof.
    Type: Application
    Filed: December 11, 2015
    Publication date: May 31, 2018
    Applicants: CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS (CONICET), UNIVERSIDAD NACIONAL DE QUILMES, INIS BIOTECH LLC
    Inventors: Mirna SANCHEZ, Mariano GRASSELLI, Leandro J. MARTINEZ
  • Publication number: 20170354957
    Abstract: A process for producing propylene glycol from glycerol including a catalyst of Cu and Ce at concentrations of up to 15% of each metal. In addition, it is described a catalyst of Cu and Ce to perform the selective reduction of glycerol and the process of production of such catalyst.
    Type: Application
    Filed: December 16, 2015
    Publication date: December 14, 2017
    Applicants: CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET), UNIVERSIDAD NACIONAL DEL LITORAL, INIS BIOTECH LLC
    Inventors: Raul Alberto COMELLI, Lisandro Roberto FERRARI
  • Patent number: 9733174
    Abstract: Low-cost and easily-operated microviscometer suitable for medical diagnosis clinical studies and other fluid tests. The equipment consists of a microchannel (2) formed by concatenated microchannels made by micro-manufacturing techniques, and a fluid column position detector inside the microchannel. The microchannels are open at one end and closed at the other end and are made of a single biocompatible material. When a liquid drop is put into the inlet of the microchannel (2), the fluid enters by capillary until the compressed air pressure equals the capillary pressure plus atmospheric pressure. The fluid transient movement from entering the channel until stopping at its balance position is analyzed thus obtaining as a result the viscosity and the capillary pressure of the liquid tested.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: August 15, 2017
    Assignees: COMISION NACIONAL DE ENERGIA ATOMICA, INIS BIOTECH LLC, CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS
    Inventors: Nadim Marcelo Morhell, Hernán Pastoriza
  • Patent number: 9657298
    Abstract: Recombinant bacterial strains comprising heterologous nif genes in its genome, and capable of fixing nitrogen. The strain may be, for example, a recombinant Pseudomonas fluorescens strain comprising heterologous nif genes in its genome. An inoculum and a method for increasing plant productivity are further described.
    Type: Grant
    Filed: November 22, 2012
    Date of Patent: May 23, 2017
    Assignees: CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET), INSTITUTO NACIONAL DE TECNOLOGIA AGROPECUARIA (INTA), INIS BIOTECH LLC
    Inventors: Gabriela Cynthia Soto, Sr., Nicolas Daniel Ayub, Lorena Maria Setten
  • Patent number: 9623102
    Abstract: A vaccine for the prevention of infections with Bordetella, comprising at least outer membrane vesicles (OMVs) of B. parapertussis, excipients and/or adjuvants. Bordetella may be, for example, B. pertussis or B. parapertussis. The vaccine can comprise adjuvants, for example, aluminum hydroxide and other immunogens such as tetanus toxoid, diphtheria toxoid, or combinations thereof. In another preferred embodiment, the vaccine for the prevention of infections with Bordetella comprises at least outer membrane vesicles (OMVs) of B. pertussis and the lipopolysaccharide of B. parapertussis, excipients and/or adjuvants. The vaccine can comprise between 3 to 20 ?g per dose of OMVs from B. pertussis and between the amount equivalent to 107 and 1010 bacteria per dose of lipopolysaccharide of B. parapertussis. The adjuvant can be aluminum hydroxide and other immunogens such as tetanus toxoid, diphtheria toxoid, or combinations thereof. The Tdap vaccine exhibits cross activity.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: April 18, 2017
    Assignees: CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECHNICAS (CONICET), UNIVERSIDAD NACIONAL DE LA PLATA, INIS BIOTECH LLC
    Inventors: Daniela Hozbor, Daniela Bottero, María Emilia Gaillard, Eugenia Zurita, Maximiliano Omazabal, Darío Flores, Agustina Errea, Griselda Moreno, Martin Rumbo, Erika Bartel, Celina Castuma
  • Patent number: 9511137
    Abstract: Adjuvant for vaccines that comprises a non-lipidated bacterial outer-membrane polypeptide (Omp), in which the bacteria may be of those of Brucella genus. The adjuvant may be a modified polypeptide or may be, for example, the Omp19S polypeptide or the Omp16S polypeptide, parts or mixtures of the two. In a preferred embodiment, the adjuvant is the non-lipidated polypeptide included in SEQ ID No: 1, or parts thereof. In a further preferred embodiment, the adjuvant is the non-lipidated polypeptide included in SEQ ID No: 2 or parts thereof.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: December 6, 2016
    Assignees: CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS, INIS BIOTECH LLC
    Inventors: Mirta L. Coria, Karina A. Pasquevich, Andres E. Ibanez, Guillermo H. Giambartolomei, Juliana Cassataro, Maria Victoria Delpino
  • Publication number: 20160318989
    Abstract: An isoform of the TGF beta receptor II comprising a sequence of about of 80 amino acids and lacking a transmembrane domain; wherein the isoform is a TGF?-1 agonist. The isoform comprises the amino acid sequence set forth in SEQ ID No. 12. The isoform may have the amino acid sequence set forth in SEQ ID No. 2 or sequences having at least 85% sequence identity to the sequence set forth in SEQ ID No. 2.
    Type: Application
    Filed: December 19, 2014
    Publication date: November 3, 2016
    Applicants: Consejo Nacional de Investigaciones Científicas y Técnicas, FUNDACIÓN ARTICULAR, INIS BIOTECH LLC
    Inventors: Ricardo Alfredo DEWEY, Benito Jorge VELASCO ZAMORA, Tania Melina RODRÍGUEZ, Alejandra CARREA, Andrea Nancy CHISARI, Marcelo Javier PERONE
  • Patent number: 9187518
    Abstract: A method of treating a solid tumor in a mammal by inhibiting angiogenesis, including administering to the mammal which has a solid tumor selected from the group consisting of breast carcinoma, lung carcinoma, prostate carcinoma, colon carcinoma, ovarian carcinoma, neuroblastoma, central nervous system tumor, multiform glioblastoma and melanoma; a composition including brassinosteroids of general formula (I) wherein can be a single or double bond and the configurations of carbon atoms C22 and C23 respectively linked to the substituents HO are S for both carbon atoms and a pharmaceutically acceptable additive.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: November 17, 2015
    Assignees: CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET), INIS BIOTECH LLC
    Inventors: Javier Alberto Ramirez, Flavia Mariana Michelini, Lydia Raquel Galagovsky, Alejandro Berra, Laura Edith Alche
  • Patent number: 8993310
    Abstract: A device for diagnosis of physiologic status and/or selection of best spermatozoa of a semen sample based on chemotaxis, and the procedure of thereof, enabling by a simple and inexpensive device the diagnosis and selection of the best spermatozoa in only one step. Only needed are: the present device, a regular light microscope, and personnel with elementary knowledge of laboratory management. The device is of the type having two communicated compartments (1a, 1b), and where said compartments (1a, 1b) communication occurs through a duct or bridge (2) located in the lower part, and above the lower level of mentioned compartments (1a, 1b); in the entrances of said compartments (1a, 1b) appropriate closing means (3, 4) and appropriate air output ducts (5) are placed communicating the top end of compartments (1a, 1b) with the exterior.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: March 31, 2015
    Assignees: Consejo Nacional de Investigaciones Cientificas y Technicas (CONICET), Inis Biotech LLC
    Inventors: Laura Cecilia Giojalas, Héctor Alejandro Guidobaldi, Laura Virginia Gatica, Maria Eugenia Teves, Maria del Mar Montesinos, Diego Rafael Uñates
  • Publication number: 20140216140
    Abstract: Low-cost and easily-operated microviscometer suitable for medical diagnosis clinical studies and other fluid tests. The equipment consists of a microchannel (2) formed by concatenated microchannels made by micro-manufacturing techniques, and a fluid column position detector inside the microchannel. The microchannels are open at one end and closed at the other end and are made of a single biocompatible material. When a liquid drop is put into the inlet of the microchannel (2), the fluid enters by capillary until the compressed air pressure equals the capillary pressure plus atmospheric pressure. The fluid transient movement from entering the channel until stopping at its balance position is analyzed thus obtaining as a result the viscosity and the capillary pressure of the liquid tested.
    Type: Application
    Filed: July 5, 2012
    Publication date: August 7, 2014
    Applicants: INIS BIOTECH LLC, CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET), COMISIÓN NACIONAL DE ENERGÍA ATÓMICA (CNEA)
    Inventors: Nadim Marcelo Morhell, Hernan Pastoriza
  • Patent number: 8541566
    Abstract: The invention provides promoters inducible by reactive oxygen species (ROS), capable of driving the expression of a gene of interest, particularly in a tumor cell. More particularly, it refers to promoters inducible by reactive oxygen species, that may be used to drive the expression of a gene of interest, such as a therapeutic gene, or a reporter gene for use in image diagnosis. The promoters comprise at least a fragment of a promoter sequence responsive to said reactive oxygen species, and corresponding to a gene highly expressed in cancer cells, wherein the fragment of the promoter sequence responsive to reactive oxygen species (ROS) is selected from the group of: the VE element of the VEGF promoter, the E6 element of the promoter of the EGR-1 gene, the MMP-1 element and a chimeric promoter containing an E6 element and a VE element. It also provides vectors carrying a human therapeutic or non therapeutic gene of interest, operably linked to said promoter sequence and compositions comprising the same.
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: September 24, 2013
    Assignees: Inis Biotech LLC, Fundacion Instituto Leloir, Comision Nacional de Energia Atomica (CNEA), Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)
    Inventors: Lucia Policastro, Hebe Duran, Osvaldo Podhajcer
  • Patent number: 8431554
    Abstract: Brassinosteriods, illustrated by the following exemplary compounds, are disclosed: The compounds have anti-inflammatory and antiviral activity. In pharmaceutical compositions, the compounds are useful in ophthalmic pharmaceuticals for treatment of diseases caused by adenovirus, such as epidemic keratoconjunctivitis, and herpes simplex type 1, such as herpetic stromal keratitis.
    Type: Grant
    Filed: July 4, 2008
    Date of Patent: April 30, 2013
    Assignees: Consejo Nacional de Investigaciones Cientificas y Tecnicas (Conicet), Inis Biotech LLC
    Inventors: Javier Alberto Ramirez, Flavia Mariana Michelini, Lydia Raquel Galagovsky, Alejandro Berra, Laura Edith Alche